letrozole,palbociclib
pfizer,novartis
['paloma-2']
the final os analysis of the paloma-2 study was presented at #asco22:
palbo+let vs let os is no different (53.9 vs 51.2 mos, hr:0.95) is it time to question palbo's effectiveness? there seems to be something beyond patient selection and statistical method. 
Medical Oncologist